Bellerophon Therapeutics Inc (BLPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bellerophon Therapeutics Inc (BLPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8309
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product candidate, INOpulse, a combination drug-device therapy intended for the treatment of pulmonary hypertension associated with interstitial lung disease, pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with chronic obstructive pulmonary disease. It develops INOpulse platform is based on its proprietary pulsatile nitric oxide delivery device. Bellerophon Therapeutics is headquartered in Warren, New Jersey, the US.

Bellerophon Therapeutics Inc (BLPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bellerophon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Bellerophon Therapeutics Raises Funds through Venture Financing 11
Bellerophon Therapeutics Raises Funds Through Venture Financing 12
Bellerophon Therapeutics Secures USD80 Million in Venture Funding 13
Equity Offering 14
Bellerophon Therapeutics Plans to Raise up to USD100 Million in Public offering of Securities 14
Bellerophon Therapeutics Plans to Raise Funds through Public Offering 15
Bellerophon Therapeutics Raises USD23.4 Million in Private Placement of Units 16
Bellerophon Therapeutics Raises USD3 Million in Private Placement of Shares and Warrants 18
Bellerophon Therapeutics Raises USD12 Million in Public Offering of Shares 19
Bellerophon Therapeutics Raises USD60 Million in IPO 20
Bellerophon Therapeutics Inc – Key Competitors 22
Bellerophon Therapeutics Inc – Key Employees 23
Bellerophon Therapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 01, 2018: Bellerophon provides business update and reports second quarter 2018 financial results 25
May 10, 2018: Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results 27
Mar 15, 2018: Bellerophon Reports Fourth Quarter and Full-Year 2017 Financial Results 29
Nov 07, 2017: Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results 31
Aug 07, 2017: Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update 33
May 15, 2017: Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update 35
Mar 13, 2017: Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update 37
Corporate Communications 39
Nov 30, 2017: Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bellerophon Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Bellerophon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bellerophon Therapeutics Raises Funds through Venture Financing 11
Bellerophon Therapeutics Raises Funds Through Venture Financing 12
Bellerophon Therapeutics Secures USD80 Million in Venture Funding 13
Bellerophon Therapeutics Plans to Raise up to USD100 Million in Public offering of Securities 14
Bellerophon Therapeutics Plans to Raise Funds through Public Offering 15
Bellerophon Therapeutics Raises USD23.4 Million in Private Placement of Units 16
Bellerophon Therapeutics Raises USD3 Million in Private Placement of Shares and Warrants 18
Bellerophon Therapeutics Raises USD12 Million in Public Offering of Shares 19
Bellerophon Therapeutics Raises USD60 Million in IPO 20
Bellerophon Therapeutics Inc, Key Competitors 22
Bellerophon Therapeutics Inc, Key Employees 23

List of Figures
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bellerophon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bellerophon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Bellerophon Therapeutics Inc (BLPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MAEC-Kazatomprom LLP:企業の戦略的SWOT分析
    MAEC-Kazatomprom LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析
    Summary Ocugen Inc (Ocugen), formerly Histogenics Corp, is a biopharmaceutical company that discovers, develops and commercializes transformative drugs for the treatment of eye diseases. The company’s lead product candidate, OCU300, is a small molecule therapeutic intended for the treatment of ocula …
  • Jardine Lloyd Thompson Group plc:企業の戦略・SWOT・財務分析
    Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report Summary Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Daewoo Shipbuilding & Marine Engineering Co Ltd:戦略・SWOT・企業財務分析
    Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Biotron Ltd (BIT):企業の財務・戦略的SWOT分析
    Biotron Ltd (BIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • nLife Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops proprietary neuronal specific oligonucleotides as therapeutic agents for the treatment of central nervous system disorders. Its lead candidate NLF-PD-1233 is a first in class oligonucleotide …
  • YO Sushi UK Ltd:企業の戦略・SWOT・財務情報
    YO Sushi UK Ltd - Strategy, SWOT and Corporate Finance Report Summary YO Sushi UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • The Reject Shop Limited (TRS):企業の財務・戦略的SWOT分析
    The Reject Shop Limited (TRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Mercachem Holding bv:製薬・医療:M&Aディール及び事業提携情報
    Summary Mercachem Holding BV (Mercachem) is a research company that offers transparent chemistry services. The company provides services in the areas of discovery chemistry, medicinal chemistry, parallel chemistry and process research. Its parallel chemistry services include library design, chemical …
  • JACCS Co Ltd:企業の戦略・SWOT・財務分析
    JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report Summary JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • SBS Transit Ltd.:企業の戦略・SWOT・財務情報
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • BNC Bancorp:企業のM&A・事業提携・投資動向
    BNC Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNC Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Fujirebio Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Fujirebio Diagnostics Inc (FDI), a subsidiary of Fujirebio Inc is a healthcare diagnostic company that develops, manufactures and markets in-vitro diagnostic products and biomarker assays. The company’s products include manual kits, EIA kits, OEM custom solutions, multi-constituent controls, …
  • Biofrontera AG (B8F):医療機器:M&Aディール及び事業提携情報
    Summary Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and commercializes dermatological medications and medical cosmetics. The company’s products comprise Ameluz, BF-RhodoLED and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic kerat …
  • HitGen LTD:企業のM&A・事業提携・投資動向
    HitGen LTD - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HitGen LTD Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • China National Offshore Oil Corporation:企業のM&A・事業提携・投資動向
    China National Offshore Oil Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China National Offshore Oil Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • New York Power Authority:企業の戦略・SWOT・財務分析
    New York Power Authority - Strategy, SWOT and Corporate Finance Report Summary New York Power Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Xeltis AG:企業の製品パイプライン分析2018
    Summary Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process refe …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆